RECRUITING

EEG Biomarkers for OUD: Diagnostic, Prognostic, and Predictive Applications

Description

The US is suffering from a national opioid epidemic characterized by significant costs, overdoses, and deaths. Conventional Opioid Use Disorder (OUD) treatments (i.e., pharmacological and psychosocial interventions) are characterized by limited or diminishing efficacy, ceiling effects, and/or serious side effects. The availability of validated OUD biomarkers would be a key step in the development and approval of better treatments. Ultimately, the scarcity of OUD biomarkers represents a significant unmet need in the fight against opioid addiction as recognized by NIDA and the FDA with their support for development of Medical Device Development Tools (MDDT) and biomarker tests for OUD. Advances in neuroimaging techniques, and in particular recent evidence supports electroencephalography (EEG) as a promising candidate to investigate the correlation between addiction and brain state. To address the clear medical and market need for OUD biomarkers, this is a feasibility study to identify and assess potential EEG biomarkers for OUD diagnoses, disease monitoring, and prediction of OUD treatment response.

Conditions

Opiod Use Disorder
Talk to us

Related Conditions:

Opiod Use Disorder

Study Overview

On this page

Study Details

Study overview

The US is suffering from a national opioid epidemic characterized by significant costs, overdoses, and deaths. Conventional Opioid Use Disorder (OUD) treatments (i.e., pharmacological and psychosocial interventions) are characterized by limited or diminishing efficacy, ceiling effects, and/or serious side effects. The availability of validated OUD biomarkers would be a key step in the development and approval of better treatments. Ultimately, the scarcity of OUD biomarkers represents a significant unmet need in the fight against opioid addiction as recognized by NIDA and the FDA with their support for development of Medical Device Development Tools (MDDT) and biomarker tests for OUD. Advances in neuroimaging techniques, and in particular recent evidence supports electroencephalography (EEG) as a promising candidate to investigate the correlation between addiction and brain state. To address the clear medical and market need for OUD biomarkers, this is a feasibility study to identify and assess potential EEG biomarkers for OUD diagnoses, disease monitoring, and prediction of OUD treatment response.

Developing EEG Biomarkers for OUD Diagnostic, Prognostic, and Predictive Purposes

EEG Biomarkers for OUD: Diagnostic, Prognostic, and Predictive Applications

Condition
Opiod Use Disorder
Intervention / Treatment

-

Contacts and Locations

Chicago

Clinical & Imaging Research Outcomes Lab, Chicago, Illinois, United States, 60612

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * For OUD Subjects:
  • 1. Providing informed consent to participate in the study.
  • 2. 22 to 85 years old.
  • 4. Lives in immediate area with no plans to relocate.
  • 1. Providing informed consent to participate in the study.
  • 2. 22 to 85 years old.
  • 3. Lives in immediate area with no plans to relocate
  • * For OUD Subjects:
  • 1. Recently started on antiepileptic drug therapy.
  • 2. Ingestion of poppy seeds or herbal teas containing Papaveris fructus (may cause a positive opiate test for morphine, codeine \[72,73\]).
  • 3. History of neurological disorders involving stroke, brain tumors, or epilepsy as self- reported.
  • 4. History of unexplained fainting spells as self-reported.
  • 5. History of head injury resulting in more than a momentary loss of consciousness as self-reported.
  • 6. History of brain surgery as self-reported.
  • 7. Suffering from severe depression.
  • 8. Active malignancy.
  • 1. Recently started on antiepileptic drug therapy.
  • 2. History of neurological disorders involving stroke, brain tumors, or epilepsy as self- reported.
  • 3. History of unexplained fainting spells as self-reported.
  • 4. History of head injury resulting in more than a momentary loss of consciousness as self-reported.
  • 5. History of brain surgery as self-reported.
  • 6. Suffering from severe depression.
  • 7. Active malignancy.

Ages Eligible for Study

22 Years to 85 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of Illinois at Chicago,

Study Record Dates

2025-09-15